Wikipedia
Racotumomab (trade name Vaxira) is a therapeutic cancer vaccine for the treatment of solid tumors that is currently under clinical development by Recombio, an international public-private consortium with the participation of the Center of Molecular Immunology at Havana, Cuba (CIM) and researchers from Buenos Aires University and National University of Quilmes in Argentina. It induces the patient's immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.
Racotumomab triggers an immune response against the tumor antigen N-glycolil (NGc) GM3 (NGcGM3), a type of ganglioside present on the cell surface of malignant cells from lung and breast, melanoma, as well as neuroectodermal pediatric tumors. Racotumomab has successfully completed a proof-of concept clinical trial in advanced non-small cell lung cancer (NSCLC) and is currently being tested in a large, multinational study for the same indication.